In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Idenix Pharmaceuticals Inc.

Division of Merck & Co. Inc.
www.idenix.com

Latest From Idenix Pharmaceuticals Inc.

Merck Buys Peloton On Eve Of IPO, Expands Kidney Cancer Portfolio

Investors in Peloton, which has the only clinical-stage HIF-2α inhibitor, will get back 3.5 times the $304m in venture capital invested in the firm via the $1.1bn that Merck is paying up front. With all $1.15bn in additional milestone fees, the return could grow to 7.2x.

Deals M & A

Finance Watch: Alternative Funding Sources Crucial Even Amidst A Biopharma VC Boom

Private Company Edition: Investments by CIRM, the GHIT fund and the European Investment Bank back early-stage science and treatments for neglected diseases. Also, Versant Ventures raises $700m in two funds. In VC deals, Akero raised $70m, Impel NeuroPharma brought in $67.5m.

Financing StartUps and SMEs

Early Stage Candidates Carving Out New Routes In Cystic Fibrosis

Scrip spoke to two companies from a fresh wave of innovators that are approaching drug development for cystic fibrosis from a new angle.

Respiratory Research and Development Strategies

Vertex Set To Dominate Cystic Fibrosis Market For The Next Decade

Vertex is set to reap huge benefits from its triple combination program for cystic fibrosis over the next 10 years, potentially becoming the biggest selling drug in this disease, according to a new report from Datamonitor Healthcare.

Respiratory Market Intelligence
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Novirio Pharmaceuticals Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Merck & Co. Inc.
  • Senior Management
  • Daniella Beckman, SVP, CFO
    Douglas L Mayers, MD, EVP, CMO
    Eric Hoffman, VP, Corp. & Bus. Dev.
  • Contact Info
  • Idenix Pharmaceuticals Inc.
    Phone: (617) 995-9800
    320 Bent St., 4th Fl.
    Cambridge, MA 02141-2025
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register